Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
المؤلفون المشاركون
Marini, Carmine
Totaro, Rocco
Di Carmine, Caterina
Costantino, Gianfranco
Fantozzi, Roberta
Bellantonio, Paolo
Fuiani, Aurora
Mundi, Ciro
Ruggieri, Stefano
Carolei, Antonio
المصدر
Multiple Sclerosis International
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-07-22
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objective.
The aim of this prospective observational multicenter postmarketing study was to evaluate fingolimod efficacy in a real world clinical setting.
Methods.
One hundred forty-two subjects with relapsing-remitting multiple sclerosis (RRMS) were enrolled in three multiple sclerosis centers throughout Central and Southern Italy between January 2011 and September 2013.
After enrollment, regular visits and EDSS assessment were scheduled every 3 months, and MRI scan was obtained every 12 months.
Patients were followed up from 1 to 33 months (mean 14.95 ± 9.15 months).
The main efficacy endpoints included the proportion of patients free from clinical relapses, from disability progression, from magnetic resonance imaging activity, and from any disease activity.
Results.
Out of 142 patients enrolled in the study, 88.1% were free from clinical relapse and 69.0% were free from disability progression; 68.5% of patients remained free from new or newly enlarging T2 lesions and 81.7% of patients were free from gadolinium enhancing lesions.
Overall the proportion of patients free from any disease activity was 41.9%.
Conclusions.
Our data in a real world cohort are consistent with previous findings that yield convincing evidence for the efficacy of fingolimod in patients with RRMS.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Totaro, Rocco& Di Carmine, Caterina& Costantino, Gianfranco& Fantozzi, Roberta& Bellantonio, Paolo& Fuiani, Aurora…[et al.]. 2015. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. Multiple Sclerosis International،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1075285
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Totaro, Rocco…[et al.]. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. Multiple Sclerosis International No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1075285
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Totaro, Rocco& Di Carmine, Caterina& Costantino, Gianfranco& Fantozzi, Roberta& Bellantonio, Paolo& Fuiani, Aurora…[et al.]. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. Multiple Sclerosis International. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1075285
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1075285
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر